MD Anderson Cancer Center
In October 2015, OncoResponse announced a broad strategic alliance with MD Anderson Cancer Center. As part of this alliance, MD Anderson will provide access to samples and physiologic, prognostic and genotypic data from patients that have responded well to cancer immunotherapies, along with oncology and translational medicine expertise.
Oregon Health & Science University
In January 2016, OncoResponse initiated a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU). The agreement provides OncoResponse with access to OHSU patient samples in two cancer indications, prostate cancer and chronic myeloid leukemia (CML), for immune repertoire screening to identify antibodies with exceptional reactivity from patients who have elite responses to cancer immunotherapies.
In October 2015, OncoResponse licensed the I-STAR™ immune repertoire screening technology from Theraclone Sciences for the identification of therapeutic antibodies against novel targets from immuno-oncology treated patients. I-STAR technology rapidly screens antibodies made by the human immune system to identify those with exceptional reactivity that may lead to cancer treatment development.